$GKOS News

UBS Maintains Neutral on Glaukos, Raises Price Target to $172

HC Wainwright & Co. Maintains Buy on Glaukos, Raises Price Target to $195

Citigroup Maintains Buy on Glaukos, Raises Price Target to $188

Piper Sandler Reiterates Overweight on Glaukos, Raises Price Target to $195

Stifel Maintains Buy on Glaukos, Raises Price Target to $190

Truist Securities Maintains Buy on Glaukos, Raises Price Target to $215

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $178

Needham Maintains Buy on Glaukos, Raises Price Target to $201

BTIG Maintains Buy on Glaukos, Raises Price Target to $193

Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript

Glaukos Raises FY2026 Sales Guidance from $620.000M-$635.000M to $680.000M-$700.000M vs $629.748M Est

Glaukos Q2 Adj. EPS $(0.14) Beats $(0.22) Estimate, Sales $185.610M Beat $150.978M Estimate

Glaukos: A Further Guidance Hike On Revenues Could Spike Shares Post Q2 Release

Glaukos Completes Patient Enrollment In US 510(k) Pivotal Study Evaluating PRESERFLO MicroShunt In Adult Patients With Primary Open-Angle Glaucoma Who Failed Previous Medical And Surgical Treatment

Stifel Maintains Buy on Glaukos, Raises Price Target to $175

Truist Securities Maintains Buy on Glaukos, Raises Price Target to $180

Citigroup Maintains Buy on Glaukos, Raises Price Target to $175

HC Wainwright & Co. Initiates Coverage of Glaukos (GKOS) with Buy Recommendation

HC Wainwright & Co. Initiates Coverage On Glaukos with Buy Rating, Announces Price Target of $168

Piper Sandler Reiterates Overweight on Glaukos, Maintains $165 Price Target